Fresenius Medical Care has named Shervin J. Korangy as its new chief executive, with the incoming Fresenius Medical Care CEO taking office on October 12, 2026, as the world’s largest dialysis provider pivots from a sweeping restructuring programme to a new phase of profitable growth.
FAKTA
- Shervin J. Korangy, 51, becomes CEO and Chair of the Management Board of Fresenius Medical Care, effective October 12, 2026.
- He succeeds Helen Giza, 58, who led the company as CEO for four years after three years as chief financial officer.
- Under Giza, the FME25+ transformation programme cut the company’s cost base by around EUR 1.2 billion.
- Korangy most recently led BVI Medical as CEO and spent 14 years at Blackstone; he has served on FME’s Supervisory Board since 2023.
- Fresenius Medical Care operates 3,513 dialysis clinics treating about 290,000 patients worldwide.
Leadership Change Takes Effect on October 12
Fresenius Medical Care announced on October 7, 2026, that its Supervisory Board had unanimously appointed Shervin J. Korangy as chief executive officer and Chair of the Management Board. The appointment, made public from the company’s headquarters in Bad Homburg, Germany, takes effect on October 12, 2026.
Korangy succeeds Helen Giza, who is stepping down after four years as CEO. Giza joined the top job after three years as the company’s chief financial officer, meaning she departs after seven years in the company’s senior leadership.
Who Is Shervin Korangy?
Korangy is described by the company as a seasoned global executive with extensive leadership experience in healthcare and life sciences. Most recently, he served as CEO of US-based BVI Medical, which he transformed into a global leader in surgical eye care.
Earlier in his career, Korangy spent 14 years at Blackstone, the investment firm, where he focused on restructuring and private equity, and held senior executive roles at Novartis. He is no stranger to Fresenius Medical Care: he has served on the company’s Supervisory Board since 2023, giving him direct insight into the dialysis business and its strategic challenges.
According to the company, Korangy brings a strong track record in global expansion, portfolio innovation and strategic transformation across complex international organisations — experience the Supervisory Board sees as central to the company’s next phase.
From Restructuring to Profitable Growth
The leadership change marks a clear strategic pivot. Under Helen Giza, Fresenius Medical Care concentrated on repair: the FME25+ transformation programme reshaped the organisation, streamlined processes, optimised the portfolio and reduced the cost base by around EUR 1.2 billion, making the company more efficient, profitable and resilient.
With that foundation in place, the company says it will now focus on accelerating long-term profitable growth, advancing innovation, strengthening its market leadership and creating sustainable value for patients, customers and shareholders.
| Company fact | Figure |
|---|---|
| Headquarters | Bad Homburg, Germany |
| Dialysis clinics worldwide | 3,513 |
| Patients treated | About 290,000 |
| Cost base cut under FME25+ | Around EUR 1.2 billion |
| New CEO effective | October 12, 2026 |
Fresenius Medical Care describes itself as the world’s leading provider of products and services for individuals with renal diseases, serving a global dialysis patient population of around 4.5 million. Its shares are listed in Frankfurt and on the New York Stock Exchange.
For investors and the roughly 290,000 patients who depend on its clinics, the question now is how quickly Korangy’s growth agenda can translate the leaner organisation built under Giza into sustained top-line expansion.
Related Articles
Read more: General Dynamics Names Danny Deep as Next CEO, Novakovic to Become Executive Chair
